FRIDAY, Jan. 14, 2022 -- For patients with bacteremic urinary tract infections (bUTIs) due to multidrug-resistant (MDR) Escherichia coli, fosfomycin is not noninferior to comparators, with an increased rate of adverse event-related discontinuations, according to a study published online Jan. 13 in JAMA Network Open. Jesús Sojo-Dorado, M.D., Ph.D., from the Universidad...
Read Full StoryIf the content contained herein violates any of your rights, including those of copyright, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com
Top News
comments